The Effects of Soy Supplementation on Gene Expression in Breast Cancer: A Randomized Placebo-Controlled Study

Shike, Moshe; Doane, Ashley S.; Russo, Lianne; Cabal, Rafael; Reis‐Filho, Jorge S.; Gerald, William L.; Cody, Hiram S.; Khanin, Raya; Bromberg, Jacqueline; Norton, Larry

doi:10.1093/jnci/dju189

Cited by 107 publications

(93 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, recent study has also indicated that genistein governed the expression of Cdc20, leading to control of cell cycle in breast cancer cells (Zhang et al, 2015). Interestingly, emerging evidence has shown that genistein upregulated many genes involved in cell cycle such as Cdc20 in breast cancer patients (Shike et al, 2014). Therefore, it is necessary to further determine the role of genistein in breast cancer and whether inhibition of Cdc20 is the major signaling pathway through which genistein exerts its anti-cancer effects.…”

Section: Targeting Cdc20 For Cancer Therapiesmentioning

confidence: 99%

Targeting Cdc20 as a novel cancer therapeutic strategy

Wang

Zhang

Wan

et al. 2015

Pharmacology & Therapeutics

207

176

View full text Add to dashboard Cite

The Anaphase Promoting Complex (APC, also called APC/C) regulates cell cycle progression by forming two closely related, but functionally distinct E3 ubiquitin ligase sub-complexes, APCCdc20 and APCCdh1, respectively. Emerging evidence has begun to reveal that Cdc20 and Cdh1 have opposing functions in tumorigenesis. Specifically, Cdh1 functions largely as a tumor suppressor, whereas Cdc20 exhibits an oncogenic function, suggesting that Cdc20 could be a promising therapeutic target for combating human cancer. However, the exact underlying molecular mechanisms accounting for their differences in tumorigenesis remain largely unknown. Therefore, in this review, we summarize the downstream substrates of Cdc20 and the critical functions of Cdc20 in cell cycle progression, apoptosis, ciliary disassembly and brain development. Moreover, we briefly describe the upstream regulators of Cdc20 and the oncogenic role of Cdc20 in a variety of human malignancies. Furthermore, we summarize multiple pharmacological Cdc20 inhibitors including TAME and Apcin, and their potential clinical benefits. Taken together, development of specific Cdc20 inhibitors could be a novel strategy for the treatment of human cancers with elevated Cdc20 expression.

show abstract

Section: Targeting Cdc20 For Cancer Therapiesmentioning

confidence: 99%

Targeting Cdc20 as a novel cancer therapeutic strategy

Wang

Zhang

Wan

et al. 2015

Pharmacology & Therapeutics

207

176

View full text Add to dashboard Cite

show abstract

“…De récentes études ont montré que ni les protéines de soja, ni les aliments au soja, ni les compléments alimentaires d'isoflavones n'ont d'effet sur des marqueurs du risque de cancer du sein comme la densité mammographique (Hooper, 2010 ;Wu, 2015) ou la prolifération des cellules mammaires (Khan et al, 2012 ;Palomares, 2004 ;Sartippour, 2004 ;Shike, 2014).…”

Section: En Cas D'antécédents De Cancer Du Seinunclassified

Les aliments au soja : consommation en France, qualités nutritionnelles et données scientifiques récentes sur la santé

Chevalier¹,

Debeuf²,

Joubrel³

et al. 2016

OCL

View full text Add to dashboard Cite

Résumé -Aujourd'hui, 4 Français sur 10 consomment des aliments au soja. Les consommateurs les ont intégrés dans leur alimentation, sans bouleverser leurs habitudes alimentaires, parce qu'ils les considèrent naturels et sains. Les non consommateurs sont en attente de plus d'informations (origine géographique du soja et qualités nutritionnelles). La consommation est assez récente et devrait progresser dans les prochaines années. Les aliments élaborés à partir de la graine de soja fournissent des protéines de très bonne qualité nutritionnelle, des acides gras insaturés, des fibres, des vitamines et des minéraux. La graine de soja contient des isoflavones, dont une grande partie est éliminée lors de l'élaboration des aliments au soja (qui en contiennent 1 à 3 mg/g de protéine). La consommation actuelle d'aliments au soja est largement compatible avec l'apport maximal de 1mg/kg/j recommandé par l'Afssa en 2005. Le développement infantile avec les préparations à base de protéines de soja est comparable à celui observé avec celles à base de protéines de lait de vache ou avec le lait maternel, sur tous les paramètres étudiés (croissance, santé osseuse et fonctions métaboliques, reproductives, endocrines, immunitaires et neurologiques). Les aliments au soja semblent exercer un effet protecteur vis-à-vis du risque de cancer du sein (probablement lié aux isoflavones), surtout si la consommation est débutée avant l'adolescence. Chez les femmes ayant des antécédents de cancer du sein, l'alimentation peut intégrer les aliments au soja. Introduire des aliments à base de soja dans l'alimentation contribue aussi à maintenir la santé cardiovasculaire, du fait de leur effet favorable sur le taux de LDL-cholestérol, sur la fonction endothéliale, et potentiellement sur la tension artérielle. Mots clés :Alimentation / soja / consommation / nutrition / santé Abstract -Soyfoods: consumption in France, nutritional qualities and recent scientific data on its contribution to health. Today, 4 French people out of 10 eat soyfoods. Consumers have adopted them in their diet, without changing their habits, because they consider them natural and healthy. The non-users are waiting for more information (geographical origin, nutritional benefits). The consumption is relatively new and is expected to grow in the coming years. Soyfoods produced from soybeans provide high quality proteins, unsaturated fatty acids, fibres, vitamins and minerals. Soybeans contain isoflavones, much of which is lost during the production of soyfoods, which contain between 1 and 3 mg per g protein. The current consumption of soyfoods is largely consistent with the maximum intake of 1 mg/kg/day recommended by the Afssa in 2005. Infant development with formulas based on soy protein is similar to that observed with those based on cow milk or with breast milk, on all studied parameters (growth, bone health and metabolic, reproductive, endocrine, immune and neurological functions). Soyfoods may have a protective effect against the risk for breast cancer (probably due to isofla...

show abstract

“…During the process of screening of the literature for inclusion in the systematic review for the current risk assessment, the Panel became aware of a randomised placebo-controlled study (Shike et al, 2014) conducted in women with diagnosed breast cancer confirmed by biopsy. This study did not meet the inclusion criteria specified in the systematic review protocol (minimum 3 months' treatment) because duration of treatment from the date of diagnosis to the date of breast surgery varied between 7 and 30 days.…”

Section: Discussion On Results From Human Studies On the Mammary Glandmentioning

confidence: 99%

Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones

2015

EFSA Journal

View full text Add to dashboard Cite

The EFSA ANS Panel was asked to deliver a scientific opinion on the possible association between the intake of isoflavones from food supplements and harmful effects on mammary gland, uterus and thyroid in peri-and post-menopausal women. Isoflavones are naturally occurring substances which can be found in, among other sources, soy, red clover and kudzu root. The main isoflavones are genistein, daidzein, glycitein, formononetin, biochanin A and puerarin. Their chemical structures are related to 17β-oestradiol and they possess oestrogenic properties. Furthermore, isoflavones may interact with the synthesis of thyroid hormone. Food supplements targeted at peri-and postmenopausal women typically provide a daily dose of isoflavones in the range of 35-150 mg/day. A systematic review was performed to investigate whether an association could be found between intake of isoflavones from food supplements and adverse effects on the three target organs in periand post-menopausal women. The human data did not support the hypothesis of an increased risk of breast cancer from observational studies nor of an effect on mammographic density nor on proliferation marker Ki-67 expression in interventional studies. No effect was found on endometrial thickness and histopathological changes in the uterus up to 30 months of supplementation with 150 mg/day of soy isoflavones. After 60 months some non-malignant histopathological changes were reported. Thyroid hormones levels were not changed following intake of isoflavones from food supplements. The background exposure from the diet in the general European population was estimated to be lower than 1 mg/day, whereas in consumers of soy-based foods it could be higher. The Panel concluded that it was not possible to derive a single health-based guidance value for the different preparations in post-menopausal women. However the doses used in the intervention studies and their duration could serve as guidance for the intake of food supplements.

show abstract

The Effects of Soy Supplementation on Gene Expression in Breast Cancer: A Randomized Placebo-Controlled Study

Cited by 107 publications

References 39 publications

Targeting Cdc20 as a novel cancer therapeutic strategy

Targeting Cdc20 as a novel cancer therapeutic strategy

Les aliments au soja : consommation en France, qualités nutritionnelles et données scientifiques récentes sur la santé

Risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones

Contact Info

Product

Resources

About